Search Results

You are looking at 231 - 240 of 489 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

Testicular Cancer, Version 2.2015

Robert J. Motzer, Eric Jonasch, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Sam S. Chang, Toni K. Choueiri, Brian A. Costello, Ithaar H. Derweesh, Shilpa Gupta, Steven L. Hancock, Jenny J. Kim, Timothy M. Kuzel, Elaine T. Lam, Clayton Lau, Ellis G. Levine, Daniel W. Lin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Elizabeth R. Plimack, Edward N. Rampersaud, Bruce G. Redman, Charles J. Ryan, Joel Sheinfeld, Brian Shuch, Kanishka Sircar, Brad Somer, Richard B. Wilder, Mary Dwyer, and Rashmi Kumar

are 4 cycles of TIP (paclitaxel, ifosfamide, cisplatin) 80 or 4 cycles of VeIP (vinblastine, ifosfamide, cisplatin). 78 , 79 According to the NCCN Guidelines, second-line therapy for seminoma and nonseminoma is similar. It is discussed subsequently

Full access

Testicular Cancer

Robert J. Motzer, Neeraj Agarwal, Clair Beard, Sam Bhayani, Graeme B. Bolger, Mark K. Buyyounouski, Michael A. Carducci, Sam S. Chang, Toni K. Choueiri, Shilpa Gupta, Steven L. Hancock, Gary R. Hudes, Eric Jonasch, Timothy M. Kuzel, Clayton Lau, Ellis G. Levine, Daniel W. Lin, Kim A. Margolin, M. Dror Michaelson, Thomas Olencki, Roberto Pili, Thomas W. Ratliff, Bruce G. Redman, Cary N. Robertson, Charles J. Ryan, Joel Sheinfeld, Jue Wang, and Richard B. Wilder

feasible, is second-line chemotherapy (category 2A). Cisplatin-based combination chemotherapy is used for second-line treatment. 64 – 66 The regimens are 4 cycles of TIP (paclitaxel, ifosfamide, cisplatin) 67 or 4 cycles of VeIP (vinblastine, ifosfamide

Full access

Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology

Timothy Gilligan, Daniel W. Lin, Rahul Aggarwal, David Chism, Nicholas Cost, Ithaar H. Derweesh, Hamid Emamekhoo, Darren R. Feldman, Daniel M. Geynisman, Steven L. Hancock, Chad LaGrange, Ellis G. Levine, Thomas Longo, Will Lowrance, Bradley McGregor, Paul Monk, Joel Picus, Phillip Pierorazio, Soroush Rais-Bahrami, Philip Saylor, Kanishka Sircar, David C. Smith, Katherine Tzou, Daniel Vaena, David Vaughn, Kosj Yamoah, Jonathan Yamzon, Alyse Johnson-Chilla, Jennifer Keller, and Lenora A. Pluchino

, the patient should be put under surveillance. If embryonal, yolk sac, choriocarcinoma, or seminoma elements are found in the residual mass, then 2 cycles of chemotherapy with EP; paclitaxel, ifosfamide, and cisplatin (TIP); VIP; or vinblastine

Full access

Systemic Therapy for Small Cell Lung Cancer

Benjamin Levy, Ashish Saxena, and Bryan J. Schneider

agents in relapsed/resistant SCLC include irinotecan, oral etoposide, paclitaxel, and docetaxel. Weekly irinotecan has shown a response rate of 50% and a median survival of 6.1 months in a small phase II study. 52 Oral etoposide has shown response rates

Full access

Immune Checkpoint Inhibitor Therapy in Breast Cancer

Cesar A. Santa-Maria and Rita Nanda

phase IB study in metastatic TNBC investigated atezolizumab with nab-paclitaxel, and found the ORR to be 38%. The study did not require tumor PD-L1 positivity, and responses were seen irrespective of PD-L1 status. 20 These results will be validated in

Full access

Uterine Neoplasms, Version 1.2014

Wui-Jin Koh, Benjamin E. Greer, Nadeem R. Abu-Rustum, Sachin M. Apte, Susana M. Campos, John Chan, Kathleen R. Cho, David Cohn, Marta Ann Crispens, Nefertiti DuPont, Patricia J. Eifel, Amanda Nickles Fader, Christine M. Fisher, David K. Gaffney, Suzanne George, Ernest Han, Warner K. Huh, John R. Lurain III, Lainie Martin, David Mutch, Steven W. Remmenga, R. Kevin Reynolds, William Small Jr, Nelson Teng, Todd Tillmanns, Fidel A. Valea, Nicole McMillian, and Miranda Hughes

paclitaxel. Most of these responses are mild infusion reactions (ie, skin reactions, cardiovascular reactions, respiratory or throat tightness), but more severe allergic reactions (ie, life-threatening anaphylaxis) can occur. 172 - 174 In addition, patients

Full access

Targeted/Emerging Therapies for Metastatic Non–Small Cell Lung Cancer

Leora Horn

Astellas Pharma US, Inc. References 1. Mok TS Wu YL Thongprasert S . Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma . N Engl J Med 2009 ; 361 : 947 – 957 . 2. Fukuoka M Wu YL Thongprasert S . Biomarker

Full access

Pazopanib Sensitivity in a Patient With Breast Cancer and FGFR1 Amplification

Fiona Tsui-Fen Cheng, Fu Ou-Yang, Nina Lapke, Kai-Che Tung, Yen-Kung Chen, Yuh-Yu Chou, and Shu-Jen Chen

, radiotherapy, and targeted therapy. The chemotherapeutic drugs used were vinorelbine, gemcitabine, UFUR (tegafur/uracil), CMF (cyclophosphamide, methotrexate, and fluorouracil), eribulin, capecitabine, and paclitaxel, and the endocrine drugs were goserelin

Full access

Adjuvant Chemotherapy Decisions in Clinical Practice for Early-Stage Node-Negative, Estrogen Receptor-Positive, HER2-Negative Breast Cancer: Challenges and Considerations

Gayathri Nagaraj and Cynthia X. Ma

, luminal B, HER2-enriched, and basal-like, 15 which are associated with a different clinical course and sensitivity to chemotherapy. 16 Basal-like and HER2-enriched subgroups are associated with the highest rates of pCR to paclitaxel- and doxorubicin

Full access

A Change of Heart

Crystal S. Denlinger

guidelines, visit NCCN.org 4. Romond EH Jeong JH Rastogi P . Seven-year follow-up assessment of cardiac function in NSABP B-31, a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel (ACP) with ACP plus trastuzumab